H.C. Wainwright reiterates Buy rating on Medicenna stock, maintains $2.50 target

Published 04/08/2025, 17:40
H.C. Wainwright reiterates Buy rating on Medicenna stock, maintains $2.50 target

Investing.com - H.C. Wainwright has reiterated its Buy rating and $2.50 price target on Medicenna Therapeutics (NASDAQ:MDNA) following the company’s first quarter fiscal 2026 financial report and corporate update released Friday. The target represents significant upside from the current price of $0.61, though InvestingPro data shows the stock trading near its Fair Value.

The research firm noted that Medicenna’s Phase 1/2 ABILITY-1 study evaluating its long-acting IL-2 agonist, MDNA11, remains on track to complete enrollment with top-line data expected by year-end 2025. With a market cap of $53.3 million and a current ratio of 4.94, the company maintains strong liquidity to support its clinical programs.

ABILITY-1 is designed to evaluate MDNA11 both as a monotherapy and in combination with pembrolizumab for treating solid tumors, with management planning to publish clinical data updates from both treatment approaches before year-end.

H.C. Wainwright expressed optimism about these forthcoming updates, citing positive data previously presented at the American Association of Cancer Research annual meeting in April 2025.

The company also plans to initiate a clinical program for MDNA113, a drug candidate from its BiSKIT platform, in 2026 after completing ongoing pre-clinical studies, contingent upon securing adequate funding.

In other recent news, Medicenna Therapeutics released its first quarter fiscal 2026 financial report and corporate update. The company announced that enrollment for its Phase 1/2 ABILITY-1 study, which evaluates the long-acting IL-2 agonist MDNA11, is progressing as planned. Top-line data from this study is anticipated by the end of 2025. In response to these developments, H.C. Wainwright has reiterated its Buy rating on Medicenna stock, maintaining a price target of $2.50. These updates provide investors with insights into the company’s ongoing clinical trials and analyst perspectives.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.